Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 9/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037978 | 0.89 | LMNA (0.47) | AOC3SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL6038138 | 0.89 | MAPT (0.50) | KMT2ARAB9ANPC1DDR2MAPK14 | |
| SCHEMBL6038018 | 0.87 | RAB9A (0.48) | AOC3SMN1; SMN2RAB9A | |
| SCHEMBL6038109 | 0.87 | DDR2 (0.51) | SMN1; SMN2KMT2ARAB9ANPC1DDR2 | |
| SCHEMBL5280368 | 0.87 | RAB9A (0.43) | SMN1; SMN2KMT2ARAB9ANPC1DDR2 | |
| SCHEMBL6037944 | 0.87 | LMNA (0.48) | MAOBKMT2ARAB9ANPC1DDR2 | |
| SCHEMBL5279990 | 0.86 | ROCK2 (0.46) | MAOBKMT2ARAB9ANPC1DDR2 | |
| SCHEMBL6038350 | 0.84 | DDR2 (0.42) | AOC3SMN1; SMN2RAB9ADDR2MAPK14 | |
| SCHEMBL5280650 | 0.84 | RAB9A (0.45) | SMN1; SMN2RAB9ATP53LMNA | |
| SCHEMBL6037949 | 0.84 | RAB9A (0.49) | SMN1; SMN2KMT2ARAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | AOC3 3937/4885SMN1; SMN2 3733/4885MAOB 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.